Bellicum Pharmaceuticals Receives a Buy from Cantor Fitzgerald

Cantor Fitzgerald analyst Elemer Piros maintained a Buy rating on Bellicum Pharmaceuticals (NASDAQ: BLCM) yesterday and set a price target of $18. The company’s shares closed yesterday at $7.93.

According to TipRanks.com, Piros ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -3.6% and a 46.3% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Strongbridge Biopharma Plc, and Global Blood Therapeutics.

Bellicum Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $19.60.

See today’s analyst top recommended stocks >>

Based on Bellicum Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $22.84 million. In comparison, last year the company had a GAAP net loss of $21.97 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. It’s proprietary chemical induction of dimerization technology engineers and controls components of the immune system.